Skip to main content

Table 1 Patient characteristics

From: Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 months

Patients (n) 8
Age (years) 47.0 ± 9.7
Sex ratio (M/F) 5/3
Smokers/nonsmokers 1/7
Body mass index 23.8 ± 3.1
Total plasma IgE (kU/L) 309.4 ± 218.2
Forced expiratory volume in the first second 52% pred ± 14%
Asthma control test score 11.3 ± 2.8
  1. Data are expressed as mean ± SEM